Form 4: Bristol-Myers Squibb Executive Acquires Restricted Stock Units

Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reports the acquisition of 9,858 restricted stock units (RSUs) that will vest over three years.

Summary

• Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, filed a Form 4 on March 4, 2024, reporting a transaction that occurred on March 1, 2024.
• The transaction involved the acquisition of 9,858 restricted stock units (RSUs).
• These RSUs will vest in three equal installments beginning on March 1, 2025, and each RSU converts into one share of common stock upon vesting.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The acquisition of RSUs by an executive is generally viewed as a slightly positive sign, indicating confidence in the company's future.

Positives

• The acquisition of RSUs by a company officer can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the RSUs suggests a multi-year commitment by the executive to the company's success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates an equity-based compensation component for a key executive.

Comparison to Industry Standards

• Equity compensation, such as RSUs, is a common practice among publicly traded companies like Bristol-Myers Squibb to align the interests of executives with those of shareholders.
• Companies like Pfizer, Merck, and Johnson & Johnson also utilize RSUs as part of their executive compensation packages.
• The vesting schedule of three years is fairly standard in the pharmaceutical industry.

Stakeholder Impact

• The acquisition of RSUs by a company officer can have a minor positive impact on shareholder sentiment.

Key Dates